KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...
Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this ...
Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS ...
Analysis of tumor microenvironmental features of primary and synchronous liver metastases from patients with colorectal cancer using a deep learning algorithm. Real-world analysis of the impact of ...
Overall survival of immunotherapy versus standard of care in microsatellite stable metastatic colorectal cancer: A propensity score matched analysis of 708 patients. This is an ASCO Meeting Abstract ...
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer. Among patients with heavily pretreated patients with KRAS ...
Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may limit ...
The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...
FDA has announced it has approved the first genetic test that can help some colorectal cancer patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results